This blog is based on the recent Frost & Sullivan analysis “Vascular Grafts Market, Global, 2021–2029,” authored by Vittal Bhaskar Rao, Research Manager, Healthcare & Life Sciences Practice.
An Industry in Motion: Technology, Disease Burden, and Competitive Pressure
The global vascular grafts market is undergoing rapid evolution, fueled by a confluence of technological advancements, a rising global disease burden, and intensifying competition. Between 2024 and 2029, the market is projected to grow at a CAGR of 4.3%, expanding from $3.7 billion in 2024 to $4.58 billion by 2029.
Discover how innovations in vascular grafts are transforming patient outcomes and redefining global vascular care.
In this strategic overview, we highlight the most impactful trends, technologies, and market dynamics shaping the future of vascular grafts — including segments such as aortic vascular grafts, peripheral grafts, and advanced stent grafts like AAA (abdominal aortic aneurysm) and TAA (thoracic aortic aneurysm) devices.
Global Market Overview
- Market Size (2024): $3,706.9 million
- Expected Market Size (2029): $4,583.5 million
- CAGR (2024–2029): 4.3%
- Top 5 Players Revenue Share (2024): 84.1%
Key Growth Drivers
- Rising Prevalence of Vascular Diseases
Aging populations in Asia-Pacific (APAC) and Middle East & Africa (MEA) regions are fueling demand. Conditions like hypertension, cardiovascular disease, and end-stage renal disease (ESRD) are increasingly common.
- Shift to Endovascular Techniques
Endovascular aneurysm repair (EVAR) is rapidly replacing open abdominal aneurysm repair (OAR) due to fewer complications, reduced hospital stays, and improved patient outcomes. This trend is especially strong in Germany, Australia, and the U.S.
- Early Detection Programs
Nationwide screening initiatives in the U.S., U.K., and Germany are promoting early diagnosis of aortic aneurysms, leading to increased procedure volumes and reduced emergency cases.
- Innovation in Complex Aneurysm Treatment
Fenestrated and Branched Endovascular Aortic Repair (F/BEVAR) is becoming the gold standard for complex AAA treatment, endorsed by European clinical guidelines for its safety and efficacy.
Market Challenges
- Lack of effective ≤4 mm small-diameter grafts for cardiovascular interventions.
- High installation and operational costs of robot-assisted surgical systems, especially in low-volume centers.
Competitive Landscape: Intense, Evolving and Innovation-driven
The market is witnessing intense competition between established players like:
- W.L. Gore
- Medtronic
- Cook Medical
- Terumo
- Endologix
… and disruptive challengers such as Artivion, which received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drugs Administration (FDA) for its AMDS Hybrid Prosthesis and breakthrough device designation in 2024 for treating acute DeBakey Type I dissections.
Strategic acquisitions are shaping the competitive landscape:
- W.L. Gore acquired InnAVasc Medical (Aug 2022)
- LeMaitre Vascular acquired Artegraft, Inc. (June 2020)
Industry Convergence: The Rise of Robot-assisted Endovascular Surgery
Traditionally used in general surgery and orthopedics, robot-assisted surgery is now entering vascular applications. Companies like Intuitive Surgical and Medtronic are leveraging their large robotic system footprints to pioneer robot-assisted endovascular procedures — a trend that’s expected to accelerate collaborative innovation across MedTech, robotics, and healthcare systems.
Regional Spotlight: Why APAC Is the Growth Hotspot
APAC is projected to be the fastest-growing region, driven by:
- Rapidly aging population in Japan, China, and India
- Rising incidence of vascular disease and ESRD
- Expanding access to minimally invasive procedures
- Strategic government focus on early screening and healthcare access
Opportunity: Companies should invest in surgeon training programs and public awareness campaigns to capture market share in this high-growth region.
Emerging Opportunities
Fenestrated and Branched Endovascular Aortic Repair (F/BEVAR)
- Becoming the preferred treatment for complex aneurysms
- Supported by clinical guidelines and real-world outcomes
- Drives innovation in custom and off-the-shelf stent graft design
Minimally Invasive Portfolio Expansion
- Patients and providers favor less invasive techniques
- Companies must balance product development to avoid internal cannibalization of open surgery devices
Positioning for Long-term Success
The vascular grafts market is entering a new era. The convergence of technology, competition, and patient preference is driving a shift toward minimally invasive, robotic-assisted, and customized vascular interventions.
To lead in this evolving landscape, companies must:
- Invest in innovation and clinical validation
- Expand into emerging markets, especially APAC
- Collaborate across robotics, MedTech, and healthcare ecosystems
- Balance growth between open and endovascular product lines
Let’s Talk
Is your company prepared to compete in the next generation of vascular care? Stay ahead of market dynamics and tap into growth opportunities with deep strategic insights.
Contact us today at hello@frost.com to learn how your organization can lead the future of the vascular grafts market.
